Evidence map›Paper›PMID 36713355›Full record

ArticleHemaSphere2023

Interim Positron Emission Tomography During Frontline Chemoimmunotherapy for Follicular Lymphoma.

Reid W Merryman, Laure Michaud, Robert Redd, Patrizia Mondello, Hyesun Park, Gabriela Spilberg, Matthew Robertson, Eleanor Taranto, Gulrayz Ahmed, Matthew Chase and 18 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Trial
  2. Article
  3. Baseline [BMC cancer · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 8 institutions in 1 country.

Reid W MerrymanDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Laure MichaudMolecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Robert ReddDepartment of Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Patrizia MondelloLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medicine, New York, NY, USA.
Hyesun ParkDepartment of Imaging, Dana-Farber Cancer Institute/Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Gabriela SpilbergDepartment of Imaging, Dana-Farber Cancer Institute/Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Matthew RobertsonDepartment of Imaging, Dana-Farber Cancer Institute/Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Eleanor TarantoDivision of Hematology and Oncology, Hospital of the University of Pennsylvania.
Gulrayz AhmedMedical College of Wisconsin, Milwaukee, WI, USA.
Matthew ChaseDivisions of Hematology and Medical Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
Erin JeterDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Inhye E AhnDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Jennifer R BrownDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Jennifer CrombieDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew S DavidsDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
David C FisherDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Eric JacobsenDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Caron A JacobsonDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Austin I KimDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Ann S LaCasceDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Samuel Y NgDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Oreofe O OdejideDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Erin M ParryDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Gilles SallesLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medicine, New York, NY, USA.
Andrew D ZelenetzLymphoma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY and Weill Cornell Medicine, New York, NY, USA.
Philippe ArmandDivision of Hematologic Malignancies, Dana-Farber Cancer Institute, Boston, MA, USA.
Heiko SchöderMolecular Imaging and Therapy Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Heather JaceneDepartment of Imaging, Dana-Farber Cancer Institute/Department of Radiology, Brigham and Women's Hospital, Boston, MA, USA.
Dana-Farber Cancer Institute · USMemorial Sloan Kettering Cancer Center · USBrigham and Women's Hospital · USBeth Israel Deaconess Medical Center · USCornell University · USDana-Farber Brigham Cancer Center · USHospital of the University of Pennsylvania · USMedical College of Wisconsin · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

While most patients with follicular lymphoma (FL) have excellent outcomes with frontline chemoimmunotherapy (CIT), a subset of patients will experience early progression, which is associated with poor subsequent outcomes. Novel biomarkers are needed to identify high-risk patients earlier. We hypothesized that interim positron emission tomography (PET) would predict progression-free survival (PFS) in this population. We retrospectively identified 128 patients with grade 1-3A FL who had an interim PET after 2-4 cycles of frontline CIT at 2 academic centers. PET scans were analyzed using Deauville score (DS) and change in maximum standardized uptake value (ΔSUVmax). Interim PET DS was a significant predictor of PFS (

Identifiers

PMID36713355
PMCPMC9875968
OpenAlexW4318543031

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.